Cancer Research and Treatment

Original Articles

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma: Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(4):1578-1588. Published online April 16, 2019; DOI: https://doi.org/10.4143/crt.2018.671

Purpose
Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.
Materials and Methods
From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.
Results
Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, res-pectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p < 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p < 0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]).
Conclusion
Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Citations

Citations to this article as recorded by

Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef
Cancer stem cells and angiogenesis
Yanru Yang, Jingyu Guo, Mingyang Li, Guangxin Chu, Hai Jin, Jing Ma, Qingge Jia
Pathology - Research and Practice.2024; 253: 155064. CrossRef
Renal cancer: signaling pathways and advances in targeted therapies
Aimin Jiang, Jinxin Li, Ziwei He, Ying Liu, Kun Qiao, Yu Fang, Le Qu, Peng Luo, Anqi Lin, Linhui Wang
MedComm.2024;[Epub] CrossRef
Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
Jingyang Lin, Qingxia Fang, Xiaochun Zheng, Meng Li
PLOS ONE.2023; 18(2): e0281402. CrossRef
Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
Kidney Cancer.2023; 7(1): 123. CrossRef

7,987 View
184 Download
5 Web of Science
5 Crossref

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer: Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Sardar Alam, Eleni D. Lagoudaki, Ippokratis Messaritakis, Odysseas Zoras, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos; Cancer Res Treat. 2019;51(4):1518-1526. Published online March 20, 2019; DOI: https://doi.org/10.4143/crt.2019.008

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the prognostic significance of liver kinase b1 (LKB1) loss in patients with operable colon cancer (CC).
Materials and Methods
Two hundred sixty-two specimens from consecutive patients with stage III or high-risk stage II CC, who underwent surgical resection with curative intent and received adjuvant chemotherapy with fluoropyrimidine and oxaliplatin, were analyzed for LKB1 protein expression loss, by immunohistochemistry as well as for KRAS exon 2 and BRAFV600E mutations by Sanger sequencing and TS, ERCC1, MYC, and NEDD9 mRNA expression by real-time quantitative reverse transcription polymerase chain reaction.
Results
LKB1 expression loss was observed in 117 patients (44.7%) patients and correlated with right-sided located primaries (p=0.032), and pericolic lymph nodes involvement (p=0.003), BRAFV600E mutations (p=0.024), and TS mRNA expression (p=0.041). Patients with LKB1 expression loss experienced significantly lower disease-free survival (DFS) (hazard ratio [HR], 1.287; 95% confidence interval [CI], 1.093 to 1.654; p=0.021) and overall survival (OS) (HR, 1.541; 95% CI, 1.197 to 1.932; p=0.002), compared to patients with LKB1 expressing expressing tumors. Multivariate analysis revealed LKB1 expression loss as independent prognostic factor for both decreased DFS (HR, 1.217; 95% CI, 1.074 to 1.812; p=0.034) and decreased OS (HR, 1.467; 95% CI, 1.226 to 2.122; p=0.019).
Conclusion
Loss of tumoral LKB1 protein expression, constitutes an adverse prognostic factor in patients with operable CC.

Citations

Citations to this article as recorded by

Cafestol inhibits colon cancer cell proliferation and tumor growth in xenograft mice by activating LKB1/AMPK/ULK1-dependent autophagy
Yuemei Feng, JiZhuo Yang, Yihan Wang, Xue Wang, Qian Ma, Yalin Li, Xuehui Zhang, Songmei Wang, Qiao Zhang, Fei Mi, Yanjiao Wang, Dubo Zhong, Jianzhong Yin
The Journal of Nutritional Biochemistry.2024; 129: 109623. CrossRef
The Prognostic Significance of NEDD9 Expression in Human Cancers: A Systematic Review, Meta-Analysis, and Omics Exploration
Jehad A. Yasin, Ramez M. Odat, Fares A. Qtaishat, Mohammad-Amer A. Tamimi, Muaath I. Alsufi, Osama M. Younis, Leen A. Alkuttob, Anwaar Saeed
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Phe354Leu polymorphism of the liver kinase B1 gene as a prognostic factor in adult egyptian patients with acute myeloid leukemia
Ola A. Hussein, Hany A. Labib, Rasha Haggag, Maha Mahmoud Hamed Sakr
Heliyon.2023; 9(5): e15415. CrossRef
Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study
Ippokratis Messaritakis, Eleni Psaroudaki, Konstantinos Vogiatzoglou, Maria Sfakianaki, Pantelis Topalis, Ioannis Iliopoulos, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, Maria Tzardi, John Souglakos
Cancers.2023; 15(19): 4819. CrossRef
Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
Asimina Koulouridi, Michaela Karagianni, Ippokratis Messaritakis, Maria Sfakianaki, Alexandra Voutsina, Maria Trypaki, Maria Bachlitzanaki, Evangelos Koustas, Michalis V. Karamouzis, Anastasios Ntavatzikos, Anna Koumarianou, Nikolaos Androulakis, Dimitrio
Cancers.2022; 14(14): 3320. CrossRef
Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients
Ippokratis Messaritakis, Asimina Koulouridi, Eleni Boukla, Maria Sfakianaki, Konstantinos Vogiatzoglou, Michaela Karagianni, Nikolaos Gouvas, John Tsiaoussis, Evangelos Xynos, Elias Athanasakis, Dimitrios Mavroudis, Maria Tzardi, John Souglakos
Cancers.2022; 14(18): 4407. CrossRef
Peutz-Jeghers syndrome: what has been known for 125 years of research? (review)
Tatiana A. Savelyeva, D. Yu. Pikunov, A. M. Kuzminov, A. S. Tsukanov
Koloproktologia.2021; 20(2): 85. CrossRef
PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, Stavroula Manolakou, Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitrios Mavroudis, John Tsiaoussis, Nikolaos Gouvas, John Souglakos
Cancers.2020; 12(8): 2058. CrossRef
LKB1 inactivation leads to centromere defects and genome instability via p53-dependent upregulation of survivin
Li-Yan Jin, Kui Zhao, Long-Jiang Xu, Rui-Xun Zhao, Kaitlin D. Werle, Yong Wang, Xiao-Long Liu, Qiu Chen, Zhuo-Jun Wu, Ke Zhang, Ying Zhao, Guo-Qin Jiang, Feng-Mei Cui, Zhi-Xiang Xu
Aging.2020; 12(14): 14341. CrossRef
Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review
Emma C. Hulshof, Lifani Lim, Ignace H. J. T. de Hingh, Hans Gelderblom, Henk-Jan Guchelaar, Maarten J. Deenen
Frontiers in Pharmacology.2020;[Epub] CrossRef

6,811 View
184 Download
9 Web of Science
10 Crossref

Microsatellite Instability in Korean Hepatocellular Carcinoma using Fluorescent - PCR: Young Suk Park, Hee Jung Wnag, Moon Ju Oh, Eun Ha Kim, Kyung Ok Lee, Myung Wook Kim, Young Gyu Chai; J Korean Cancer Assoc. 1998;30(3):544-552.

Abstract PDF: PURPOSE
Hepatocellular carcinoma (HCC) is one of the most common cancers in many parts of the world, however the molecular mechanisms underlying liver cell transformation remain obscure. The instability of microsatellite sequences dispersed in the genome has been linked to a deficiency in cellular mismatch repair. This phenotype has been frequently observed in various human neoplasms and is regarded as a major factor in tumorigenesis. To investigate cumulative genetic changes related with apoptosis during development and progression of HCC, we examined DNAs isolated from 12 Korean HCCs and their adjacent non-tumorous parts to look for evidence of microsatellite instability (MSI).
MATERIALS AND METHODS
Twelve microsatellite loci (D6S271, D6S426, D13S153, D13S263, D17S849, D17S938, D17S945, D18S474, D18S64, D19S420, D.19S418 and D19S210) were amplified by PCR from 12 Korean HCCs, and analyzed using an automated DNA analyzer.
RESULTS
The high percentages of the MSI were found for the loci of D6S426 (33.3%) and D17S945 (25.0%). The related genes with high frequency of MSI were noted in the wafl (41.7%) and p53 (25.0%). From this study, fifty eight percent of HCCs (7/12) showed MSI with at least one marker.
CONCLUSION
This results suggest that the analysis of MSI in HCC might be useful for identifying genes whose loss of function contributes to the development of liver cancer. Furthennore, this method may give a more rapid and accurate sizing of the PCR products of microsatellite; making the routine assessment of MSI possible in many clinical fields.

3,420 View
51 Download

First
Prev
Page of 1
Next
Last

Search